WT1 peptide vaccination for pediatric patients: phase I/II study.

WT1 peptide vaccination for pediatric patients: phase I/II study. - WT1 peptide vaccination for pediatric patients:tumor regression study.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013252

Enrollment

Registered

2014-02-25

Start date

2006-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric malignant tumor, hematological malignancy

Interventions

The patient is intradermally injected with 0.5-3 mg of the HLA-A*2402-restricted, 9-mer modified WT1 peptide (p235-243:CYTWNQMNL) emulsified with Montanide ISA51 adjuvant. The WT1 vaccination is sched

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Residual tumor is confirmed by Image after conventional therapy. HLA A2402 Wt1 positive pathologilally NCI-CTC grade 1 ps 0 to 2

Exclusion criteria

Exclusion criteria: 1) active infectious diseases 2) Severe Complications, including Heart failure, Renal faiure, Hapatic failure, ileus, uncontrolable DM, and so on 3) Other severe problems unsuitable for this study active infectious diseases

Design outcomes

Primary

Measure	Time frame
The frequency of side effect. The effectivness	—

Secondary

Measure	Time frame
WT1specific immunological reaction	—

Countries

Japan

Contacts

Public ContactYoshiko Hashii

Osaka University Graduate School of Medicine Department of Developmental Medicine (Pediatrics),

areken@ped.med.osaka-u.ac.jp06-6879-3932

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026